Highest-materiality recent filing
NRx Pharmaceuticals closes $22.3M public offering of common stock at $3.50/share
Priced 5,714,286 shares at $3.50; underwriters' option for 857,142 shares exercised, gross proceeds $22.3M.
NRx Pharma announces FDA path to NDA for NRX-100 with broader TRD+suicidality indication
FDA meeting provided clear path to submit NDA for NRX-100 under Fast Track; endpoints support full approval rather than Accelerated Approval.
Received Nasdaq letter on Jan 12, 2026 for failing to hold annual meeting within 12 months of fiscal year end.
NRx Pharmaceuticals eliminates all balance sheet debt by converting $5.4M to equity
Repaid remaining $5.4M debt to Anson Funds via equity conversion of common stock; no warrants or repricing mechanisms.
HOPE Therapeutics acquired strategic minority interest in Rebecca S. Cohen, MD, LLC (Cohen & Associates) of Sarasota, FL, effective Oct 17, 2025.
FDA grants Suitability Petition for NRx's preservative-free ketamine, enabling ANDA re-filing
FDA approved Suitability Petition for proposed strength of NRx's single-patient, preservative-free ketamine (KETAFREE™).
NRx subsidiary HOPE Therapeutics completes acquisition of Dura Medical
Dura Medical is revenue generating and EBITDA positive; operates clinics in Naples and Ft. Myers.
NRx Pharmaceuticals raises $8.8M, announces HOPE Therapeutics launch and Rockefeller advisory role
Raised $8.8M gross from experienced biotech investors via common stock offering; no warrants or variable rate features.
NRx Pharma raises $6.5M, Q2 operating loss improves to $3.7M, FDA expands Fast Track for NRX-100
Registered direct offering of 3,959,999 shares at $1.65/sh raises ~$6.5M; one-year lockup, no warrants.
FDA Fast Track for NRX-100 in suicidal depression; ANDA filing deficiency noted
FDA Fast Track designation for NRX-100 (IV ketamine) to treat suicidal ideation in depression, including bipolar depression.
NRx Pharma files ANDA for preservative-free IV ketamine; market at $750M
Filed ANDA for NRX-100 (preservative-free IV ketamine) with FDA; seeks priority review due to drug shortage.
NRx Pharmaceuticals reports Q1 net loss of $5.5M, advances NDA filings and HOPE clinic acquisitions
Net loss narrowed to $5.5M for Q1 2025 from $6.5M in Q1 2024; operating loss $3.8M vs $6.0M.
Kadima is a profitable interventional psychiatry clinic in La Jolla, CA, expected to serve as clinical model for HOPE network.
Q4 2024 operating loss $2.4M, down 45% YoY; FY2024 operating loss $18.5M vs $27.8M in 2023.
NRx Pharma secures $27M financing for subsidiary Hope Therapeutics clinic rollup
Private placement of 732,600 shares at $2.73/share for $2M immediate funding.
Issued $5.435M senior secured notes (net proceeds ~$5M) and warrants for 862,699 shares at $3.78 strike; registered direct offering of 1,215,278 shares at $2.88/share.
NRx regains Nasdaq compliance; appoints Mike Taylor director amid $25M HOPE investment term sheet
Received Nasdaq notice on Jan 17 that it regained MVLS compliance; requirement met on Jan 16 after 10 consecutive trading days above $35M.
NRXP subsidiary HOPE signs $27M term sheet with Smith & Sauer; $25M preferred equity, $2M common
Smith & Sauer to purchase $25M Series A Preferred in HOPE convertible into 1/3 of fully diluted equity, with 15% dividend.
NRx Q3 net operating loss down 74% to $1.6M; on track for NDA filings by year-end
Net operating loss $1.6M in Q3 2024 vs $6.1M in Q3 2023; nine-month net loss $16.1M vs $25.8M.
NRx Pharma closes $5.435M second tranche of secured notes; cancels third tranche
On Oct 10, 2024, closed second tranche: $5.435M principal amount of Senior Secured Convertible Notes (purchase price ~$5.0M) and warrants for 1,846,128 shares.
NRx CEO resigns; Chairman Javitt takes interim CEO; shareholders approve reverse split
CEO Stephen Willard resigns effective Oct 7, 2024; Chairman Jonathan Javitt appointed interim CEO.
Stephen Willard, CEO of NRx Pharmaceuticals, recommended that the company's shareholders would be best served by a CEO with commercial pharmaceutical experience, particularly drug launch experience.
NRx Pharma narrows Q2 net loss to $7.9M; secures $10.8–16.3M convertible debt for NDAs
Q2 net loss $7.9M vs $8.7M YoY; six-month net loss $14.4M vs $19.8M.
Up to $16.3M principal in three tranches; first tranche $5.435M principal at $5M purchase price.
NRx Pharma receives Nasdaq MVLS deficiency notice; must regain compliance by Feb 3, 2025
Nasdaq notified NRx on Aug 6 that MVLS was below $35M minimum from June 14 to Aug 5, 2024.
Alvogen terminates NRX-101 pact; NRx eyes accelerated FDA filing
Alvogen terminated exclusive development and license agreement for NRX-101 effective June 21, 2024.
NRx Pharma Q1 net loss narrows to $6.5M; signs $7.5M debt term sheet to replace toxic debt
Net loss improved 41% YoY to $6.5M, from $11.0M; R&D spend down to $1.7M.
NRx receives default notice on $6.5M note; reports promising NRX-101 trial data vs lurasidone
Streeterville Capital alleges default on $11.02M convertible note; demands acceleration and repayment of at least $6,537,027.
NRx Pharma 2023 net loss $30.2M; expects top-line data this month for NRX-101 TRBD trial
Net loss for full-year 2023: $30.2M vs $39.8M in 2022; Q4 2023 loss $4.3M vs $10.2M in Q4 2022.
Reverse stock split at 1:10 ratio; shares outstanding reduced from ~95.7M to ~9.57M.
On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).
Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.
On January 7, 2025, Janet Rehnquist resigned as a member of the Board of Directors (“ Board ”) of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.
Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.
On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.
Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.
On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately
On June 13, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Dennis McBride to serve as a member of the Board of Directors of the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material